Evidence map›Paper›PMID 38990019›Full record

ArticlemBio2024

MBX-7591: a promising drug candidate against drug-resistant fungal infections.

Nivea Pereira de Sa, Maurizio Del Poeta

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nivea Pereira de SaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.ORCID 0000-0003-0901-6909
Maurizio Del PoetaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.ORCID 0000-0001-8418-3120

Funding

New antifungals targeting the synthesis of fungal sphingolipidsR01AI116420 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI Maurizio Del Poeta · 2016 to 2026
$7.6M
Lipid-mediated fungal pathogenesisR01AI125770 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2016 to 2025
$6.2M
BLRD Research Career Scientist Award ApplicationIK6BX005386 · VA · NORTHPORT VA MEDICAL CENTER · PI DEL POETA, MAURIZIO · 2021 to 2025
–
BLRD VA IK6 BX005386HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI116420HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI125770NIAID NIH HHS R01 AI116420NIAID NIH HHS R01 AI125770
6 · The paper itself

Abstract

Invasive fungal infections (IFIs) caused by pathogenic fungi pose a significant public health concern, particularly for immunocompromised individuals. Mortality rates for IFIs remain high, and currently available treatment options are limited. Existing antifungal agents often suffer from limited clinical efficacy, poor fungicidal activity within the host, potential toxicity, and increasing ineffectiveness due to emerging resistance, especially against triazole drugs, the current mainstay of antifungal treatment. A recent study has identified MBX-7591, a small molecule with promising antifungal activity against

Indexed as

Antifungal AgentsAspergillus fumigatusDrug Resistance, FungalFungiHumansInvasive Fungal InfectionsMicrobial Sensitivity TestsMycosesTriazolesAntifungal AgentsTriazolesAspergillus fumigatusdrug developmentfatty acidfungal infectionsmembrane

Identifiers

PMID38990019
PMCPMC11323553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.